Catalysts · BMY · CIK 14272 · page 3 of 3

BMY catalysts and FDA events, page 3.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on BMY PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
August 4, 2025RHUPH20BMYPrimary completionMelanomaCompletedClinicalTrials.gov
August 1, 2025luspatercept (ACE-536)BMYPrimary completionBeta-thalassemiaCompletedClinicalTrials.gov
July 31, 2025—BMYEarnings—CompletedSEC 8-K Exhibit 99.1
July 29, 2025Opdivo® (nivolumab)BMYPrimary completionClear Cell Renal Cell CarcinomaCompletedClinicalTrials.gov
July 14, 2025lonsurf (TAS-102)BMYPrimary completionColorectal NeoplasmsWithdrawnClinicalTrials.gov
June 23, 2025—BMYPDUFA date—ScheduledSEC Form 10-Q
May 26, 2025luspatercept (ACE-536)BMYPrimary completionMyeloproliferative Disorders; Myelofibrosis; Primary MyelofibrosisCompletedClinicalTrials.gov
May 23, 2025Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 23, 2025Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 22, 2025Opdivo® (nivolumab)BMYPrimary completionExtensive-stage Small Cell Lung CancerCompletedClinicalTrials.gov
May 15, 2025Zeposia (ozanimod hydrochloride)BMYPrimary completionMultiple SclerosisWithdrawnClinicalTrials.gov
April 24, 2025—BMYEarnings—CompletedSEC 8-K Exhibit 99.1
April 21, 2025—BMYPDUFA date—ScheduledSEC Form 10-K
April 17, 2025Camzyos® (mavacamten)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
April 17, 2025Eliquis (apixaban)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
April 17, 2025Eliquis (apixaban)BMYFDA approval—ApprovedopenFDA Drugs@FDA
April 8, 2025Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
April 8, 2025Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
February 6, 2025—BMYEarnings—CompletedSEC 8-K Exhibit 99.1
January 28, 2025Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
December 27, 2024Opdivo Qvantig (hyaluronidase-nvhy; nivolumab)BMYFDA approval—ApprovedopenFDA Drugs@FDA
October 3, 2024Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
September 26, 2024Cobenfy (trospium chloride; xanomeline tartrate)BMYFDA approvalTo treat schizophreniaPress ReleaseApprovedFDA Novel Drug Approvals
September 26, 2024Opdivo® (nivolumab)BMYAdvisory committee—CompletedFDA advisory committee calendar
September 26, 2024Yervoy® (ipilimumab)BMYAdvisory committee—CompletedFDA advisory committee calendar
August 30, 2024Zeposia (ozanimod hydrochloride)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
June 21, 2024Krazati (adagrasib)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
June 13, 2024AUGTYRO (repotrectinib)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
March 15, 2024ABECMA (idecabtagene vicleucel)BMYAdvisory committee—PositiveFDA advisory committee calendar
March 6, 2024Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
January 26, 2024Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
November 15, 2023AUGTYRO (repotrectinib)BMYFDA approvalTo treat ROS1-positive non-small cell lung cancerApprovedFDA Novel Drug Approvals
October 30, 2023Orencia (abatacept)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
October 13, 2023Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
August 28, 2023Reblozyl (luspatercept-aamt)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
June 15, 2023Camzyos® (mavacamten)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
February 15, 2023Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
February 15, 2023Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
December 12, 2022Krazati (adagrasib)BMYFDA approval—ApprovedFDA Novel Drug Approvals
September 9, 2022Sotyktu (deucravacitinib)BMYFDA approvalTo treat moderate-to-severe plaque psoriasisApprovedFDA Novel Drug Approvals
July 14, 2022Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 27, 2022Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 27, 2022Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 20, 2022ONUREG (azacitidine)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 11, 2022Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 11, 2022Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
April 28, 2022Camzyos® (mavacamten)BMYFDA approvalTo treat certain classes of obstructive hypertrophic cardiomyopathyApprovedFDA Novel Drug Approvals
March 22, 2022Empliciti (elotuzumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
March 18, 2022Opdualag (nivolumab; relatlimab-rmbw)BMYFDA approvalTo treat unresectable or metastatic melanomaApprovedFDA Novel Drug Approvals
March 4, 2022Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
December 15, 2021Orencia (abatacept)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
August 19, 2021Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
July 30, 2021Romidepsin (romidepsin)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
July 15, 2021Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 27, 2021Zeposia (ozanimod hydrochloride)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 25, 2021Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 20, 2021Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
April 16, 2021Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
January 22, 2021Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
November 24, 2020Idhifa (enasidenib mesylate)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
November 20, 2020Pomalyst (pomalidomide)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
October 2, 2020Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
October 2, 2020Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
September 18, 2020Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
September 18, 2020Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
September 1, 2020ONUREG (azacitidine)BMYFDA approval—ApprovedopenFDA Drugs@FDA
July 31, 2020Evotaz (atazanavir sulfate; cobicistat)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
June 10, 2020Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 26, 2020Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 26, 2020Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 15, 2020Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 15, 2020Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 14, 2020Pomalyst (pomalidomide)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
April 3, 2020Reblozyl (luspatercept-aamt)BMYFDA approval—ApprovedopenFDA Drugs@FDA
March 25, 2020Zeposia (ozanimod hydrochloride)BMYFDA approval—ApprovedopenFDA Drugs@FDA
March 10, 2020Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
March 10, 2020Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
November 8, 2019Reblozyl (luspatercept-aamt)BMYFDA approval—ApprovedopenFDA Drugs@FDA
August 16, 2019Inrebic (fedratinib hydrochloride)BMYFDA approval—ApprovedopenFDA Drugs@FDA
August 1, 2017Idhifa (enasidenib mesylate)BMYFDA approval—ApprovedopenFDA Drugs@FDA
January 17, 2012Farxiga (dapagliflozin)BMYComplete Response Letter—CRL issuedFDA Complete Response Letters
Every catalyst is quoted from BMY’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.